齐拉西酮联用氟伏沙明治疗难治性抑郁症的临床对照研究

A comparison analysis on the efficacy of fluvoxamine combined with ziprasidone in the treatment of refractory depression

目的:观察齐拉西酮联用氟伏沙明治疗难治性抑郁症的疗效。方法:将符合条件的60例难治性抑郁症患者随机分成两组,分别给与齐拉西酮联用氟伏沙明(联用组)和单用氟伏沙明(对照组),进行12周的系统治疗,使用HAMD(汉密尔顿抑郁量表)和HAMA(汉密尔顿焦虑量表)评估其疗效;以TESS(副反应量表)和有关的实验室检查评定副反应。结果:治疗以后两组患者的HAMD评分均明显下降,联用组的治疗效果较好,两组之间差异存在显著性(P<0.01),并且联用组起效快;而两组HAMA量表的评分明显下降,联用组的治疗效果较好,两组之间差异存在显著性(P<0.01),联用组起效快,联用组的副反应发生率高于对照组,但差异无显著性;两组药物引起的副反应均为轻度或中度,表现有所不同,患者耐受性好。结论:齐拉西酮联用氟伏沙明治疗难治性抑郁症的疗效优于单独使用氟伏沙明组,且联用组起效较快,并且对于焦虑症状的改善好于对照组;两组副反应较轻,副反应的表现有所不同。联用这两种药物对于治疗难治性抑郁症具有良好的疗效,且安全性高。

Objective：To compare the efficacy of fluvoxamine combined with ziprasidone in the treatment of refractory depression.Methods：60 patients with refractory depression were randomly assigned into two groups.One group was treated with fluvoxamine and ziprasidone and the other group with fluvoxamine alone for 12 weeks.The study was conducted in order to evaluate efficacy and side effects with the HAMD（Hamilton Depressive Scale）,HAMA（Hamilton Anxiety Scale）,the TESS（treatment emergent symptom scale）and related lab tests. Results：The scores in the HAMD, HAMA were descended, the group of combining fluvoxamine and ziprasidone was better than the other group in the efficacy, and there had significant statistical differences （ P 〈0. 01 ）. The group of combining fluvoxamine and ziprasidone took effect more quickly. The side effect of using fluvoxamine and ziprasidone was higher than using fluvoxamine alone, but there were no statistical differences; The side effects caused by the two groups are all low - grade or middle - grade. The endurance of suffers is better and the appearance of side effect varies. Conclustion： The efficacy of group fluvoxamine and ziprasidone was better than the group of fluvoxamine alone, the group of combining fluvoxamine and ziprasidone took effect more quickly and had much better effect than the other group in treatment of anxiety. The side effect of the two groups was slight and the appearance of side effect varies. The combination of fluvoxamine and ziprasidone are efficacy and safety in the treatment of refractory depression.